

12 August 2021

Key Eye Co Patent Accepted by Australian Patent Examiner.

A series of patent claims have been accepted by the Australian Patent Examiner for the use of Eye Co's **Fludrocortisone Acetate** technology in the treatment of Geographic Atrophy (GA), a Macular Atrophy associated with **dry Age-Related Macular Degeneration** (dry AMD). The patent also covers combinational use with anti-VEGF technology.

Eye Co is close to concluding a Phase Ib safety study in humans involving **Fludrocortisone Acetate** in the treatment of **dry AMD** for which there are currently no available treatment options.

The granting of this patent, which expires in 2039, represents a very positive indicator of the patentability of Eye Co's core technology for this indication in other parts of the world including USA, Europe, and Asia Pacific.

Eye Co is in the business of identifying and completing early-stage development of technologies associated with the treatment of retinal diseases. The strategy is to out-license its technologies to commercialisation partners with the resources and capability to bring these technologies to patients globally. This patent will significantly facilitate this process.

Yours sincerely



Peter Abrahamson
Managing Director